Should we screen patients with hematologic malignancies for COVID-19?
Adrenal Cortex Hormones
/ administration & dosage
Antineoplastic Agents, Immunological
/ administration & dosage
COVID-19
/ complications
Clinical Decision-Making
Colony-Stimulating Factors
/ administration & dosage
Disease Management
Disease Susceptibility
/ immunology
Hematologic Neoplasms
/ complications
Humans
Immunocompromised Host
Mass Screening
Molecular Diagnostic Techniques
Molecular Targeted Therapy
/ adverse effects
Practice Guidelines as Topic
SARS-CoV-2
COVID-19
leukemia
lymphoma
multiple myeloma
polymerase chain reaction
screening
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
26
05
2020
revised:
27
06
2020
accepted:
13
07
2020
pubmed:
12
8
2020
medline:
23
2
2021
entrez:
12
8
2020
Statut:
ppublish
Résumé
The coronavirus disease (COVID-19) pandemic has posed several challenges to the hematology community to re-organize the medical care of patients with hematologic malignancies. Whereas the oncology societies favored a more or less conservative approach which considered the possibility of delaying treatment administration on a case-by-case basis, the hematology community guidelines were less stringent and recommended adequate individualized regimens. As countries are de-escalating the lockdown and the medical community is unable to foresee the end of the current outbreak will and whether the pandemic would eventually come back as a seasonal infection, there is interest in screening of patients with hematology malignancies with COVID-19 instead of limiting access to curative treatments. The rapidly accumulating knowledge about COVID-19 allows a better understanding of the diagnostic tools that may be potentially used in screening. Herein, we briefly review the pathophysiology of COVID-19, the rationale of screening of patients with hematologic malignancies, tools for screening, and available guidelines.
Identifiants
pubmed: 32779823
doi: 10.1002/hon.2780
pmc: PMC7405152
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Antineoplastic Agents, Immunological
0
Colony-Stimulating Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
648-653Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Signal Transduct Target Ther. 2020 Apr 28;5(1):57
pubmed: 32341331
Br J Haematol. 2016 May;173(3):380-93
pubmed: 27060988
J Clin Oncol. 2020 Feb 10;38(5):415-422
pubmed: 31815579
Clin Infect Dis. 2013 Jan;56(2):258-66
pubmed: 23024295
Radiology. 2020 Aug;296(2):E115-E117
pubmed: 32073353
Wien Klin Wochenschr. 2001 Feb 15;113(3-4):90-6
pubmed: 11253746
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
Lancet Respir Med. 2020 Apr;8(4):e24
pubmed: 32178774
J Geriatr Oncol. 2020 Jun;11(5):764-768
pubmed: 32331928
J Clin Virol. 2004 Dec;31(4):304-9
pubmed: 15494274
Future Oncol. 2020 Jun;16(17):1153-1156
pubmed: 32323577
J Am Coll Radiol. 2020 Jun;17(6):701-709
pubmed: 32283052
Clin Cancer Res. 2018 Sep 15;24(18):4371-4379
pubmed: 29895707
Hematol Oncol. 2016 Sep;34(3):121-32
pubmed: 27402426
Acta Haematol. 2021;144(2):132-145
pubmed: 32392559
Support Care Cancer. 2008 Nov;16(11):1299-309
pubmed: 18351398
Leuk Res. 2020 Mar 26;92:106353
pubmed: 32251934
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
PLoS Med. 2006 Sep;3(9):e343
pubmed: 16968120
Bone Marrow Transplant. 2020 Nov;55(11):2180-2184
pubmed: 32376969
Blood. 2020 May 21;135(21):1912-1915
pubmed: 32302379
Br J Haematol. 2007 Sep;138(5):563-79
pubmed: 17686051
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Front Oncol. 2020 Jul 03;10:1267
pubmed: 32719749
Oncotarget. 2016 Oct 4;7(40):65968-65981
pubmed: 27602755
Emerg Microbes Infect. 2020 Dec;9(1):687-690
pubmed: 32208840
Crit Care Med. 2003 Jan;31(1):157-65
pubmed: 12545010
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
AJR Am J Roentgenol. 2020 Oct;215(4):839-842
pubmed: 32298149
Leuk Lymphoma. 2010 Oct;51(10):1773-4
pubmed: 20849382
Hematol Oncol. 2020 Dec;38(5):648-653
pubmed: 32779823
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Signal Transduct Target Ther. 2020 Feb 21;5(1):18
pubmed: 32296012
Crit Rev Oncol Hematol. 2019 Jun;138:1-5
pubmed: 31092364
Cancer Immunol Immunother. 2006 Feb;55(2):197-209
pubmed: 16025268
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Blood. 2013 Jul 11;122(2):227-38
pubmed: 23719297
Johns Hopkins Med J. 1976 Jul;139(1):1-12
pubmed: 820917
Blood. 2014 May 29;123(22):3390-7
pubmed: 24615777
Natl Sci Rev. 2020 Jun;7(6):998-1002
pubmed: 34676125
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
Blood. 2011 Dec 22;118(26):6769-71
pubmed: 22058114
Clin Cancer Res. 2016 Jul 1;22(13):3383-97
pubmed: 26960399
Emerg Microbes Infect. 2020 Dec;9(1):386-389
pubmed: 32065057
Leukemia. 2020 Jun;34(6):1637-1645
pubmed: 32332856
Biol Blood Marrow Transplant. 2020 Jul;26(7):1239-1246
pubmed: 32298807
Acta Haematol. 2020;143(5):410-416
pubmed: 32305989
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114